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Summary 
A concise stereo-selective synthesis of a protected form of APTO 1, an unusual 
amino acid component of microsclerodermin C 2, was undertaken.  Sequential 
Sharpless Asymmetric Aminohydroxylation (AA) and Asymmetric Dihydroxylation 
(AD) reactions were used to introduce the chiral amino and hydroxyl groups.  
Specific directing groups were chosen to ensure high regio- and enantio-selectivity 
in these reactions.  The target compound was reached in a linear reaction 
sequence of fourteen steps. 
 
The strategy was designed to generate common intermediates which could be 
used to access analogous amino acid fragments in other microsclerodermins.  A 
protected form of AETD 3, from microsclerodermin E, was synthesised via a late-
stage common intermediate.  Initial studies into the modification of the sequence 
to allow access to AMPTD 4 and 10-methyl AMPTD 5 were made. 
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Nomenclature 
A. Compound Numbering and Naming 
The numbering system for intermediates is based on the numbering within the 
amino acid backbone as shown below unless specifically stated otherwise. 
                
The naming of intermediates follows the naming system provided by 
Name=Struct within the ChemDraw 9.0 Ultra software. 
B. Syn and Anti Isomers 
The syn and anti descriptors are used to describe the relative configuration of 
non-hydrogen substituents in stereoisomers.  When the carbon chain of the 
molecule is drawn in a zigzag manner in the plane of the page if the non-hydrogen 
substituents (R1, R2) are on the same side of the plane, as in A below, they are 
described as syn, and if they are on opposite sides of the plane, as in B below, 
they are designated as anti. 
 
 xii 
C. Other Stereochemical Nomenclature 
A wavy line in a structure indicates that the sample contains a mixture of 
stereoisomers as shown below for C (sp3 hybridised) and D (sp2 hybridised). 
  
(R)- and (S)- are used to describe the absolute stereochemistry at a carbon 
centre as defined by IUPAC recommendations. 
  xiii  
Abbreviations 
AA asymmetric aminohydroxylation 
Ac acetyl 
AD asymmetric dihydroxylation 
AETD (2S,3R,4S,5S,7E,9E)-3-amino-10-(4-ethoxyphenyl)- 
       2,4,5-trihydroxydeca-7,9-dienoic acid 
AIBN azobisisobutyronitrile 
AIDS acquired immunodeficiency syndrome 
AMMTD (2S,3R,4S,5S,6S,11E)-3-amino-12-(4-methoxyphenyl)- 
       6-methyl-2,4,5-trihydroxydodec-11-enoic acid 
AMPTD (2S,3R,4S,5S,6S,7E,9E,11E)-3-amino-6-methyl-12- 
       phenyl-2,4,5-trihydroxydodeca-7,9,11-trienoic acid 
APTO (2S,3R,4S,5S,7E)-3-amino-8-phenyl-2,4,5- 
       trihydroxyoct-7-enoic acid 
aq. aqueous 
AQN anthraquinone derived part of ligand 
Ar aryl 
o-Ar position on a mono-substituted aromatic ring that is  
       ortho to the substituent 
m-Ar position on a mono-substituted aromatic ring that is  
       meta to the substituent 
p-Ar position on a mono-substituted aromatic ring that is  
       para to the substituent 
q-Ar position on a mono-substituted aromatic ring where  
       the substituent is attached 
b.p. boiling point 
BF3.Et2O boron trifluoride diethyl etherate 
Bn benzyl 
Boc tert-butoxycarbonyl 
br broad 
 xiv 
brine saturated aqueous sodium chloride solution 
BT benzothiazol-2-yl 
BTSH 2-mercaptobenzothiazole 
t-Bu tert-butyl 
Bz benzoyl 
°C degree Celsius 
c concentration 
calc. calculated 
cat. catalytic 
CLB chlorobenzoyl derived part of ligand 
cm centimetre 
COSY 1H-1H correlation spectroscopy 
10-CSA (1S)-(+)-10-camphorsulfonic acid 
d doublet 
DCC 1,3-dicyclohexylcarbodiimide 
DCDM-hydantoin 1,3-dichloro-5,5-dimethylhydantoin 
DCM dichloromethane 
DEPT distortionless enhancement by polarization transfer 
DHQ dihydroquinine 
(DHQ)2AQN 1,4-bis(9-O-dihydroquininyl)-anthraquinone 
(DHQ)2PHAL 1,4-bis(9-O-dihydroquininyl)-phthalazine 
DHQD dihydroquinidine 
(DHQD)2AQN 1,4-bis(9-O-dihydroquinidinyl)-anthraquinone 
(DHQD)2PHAL 1,4-bis(9-O-dihydroquinidinyl)-phthalazine 
DIAD diisopropyl azodicarboxylate 
DIBAL-H diisobutylaluminium hydride 
dm decimetre 
DMAP 4-N,N-dimethylaminopyridine 
1,2-DME 1,2-dimethoxyethane 
DMF N,N-dimethylformamide 
2,2-DMP 2,2-dimethoxypropane 
  
  xv  
DMP Dess-Martin periodinane (1,1,1-triacetoxy-1,1-dihydro- 
 1,2-benziodoxol-3(1H)-one 
DMSO dimethyl sulfoxide 
E : Z ratio of E to Z isomers 
% ee enantiomeric excess 
EI electron impact 
eq. equivalents 
ESI electrospray ionisation 
Et ethyl 
eV electronvolt 
FT-ICR Fourier transform ion cyclotron resonance 
FTIR Fourier transform infrared 
g gram 
GABOB (3R)-4-amino-3-hydroxybutyric acid 
Grubbs cat. Grubbs second generation catalyst: (1,3-bis-(2,4,6- 
 trimethylphenyl)-2-imidazolidinylidene)dichloro  
 (phenylmethylene)(tricyclohexylphosphine)ruthenium 
h hours 
hexanes hexanes with b.p. 65 - 69 °C 
HIV human immunodeficiency virus 
HMBC heteronuclear multiple bond correlation 
HPLC high performance liquid chromatography 
HRMS high resolution mass spectroscopy 
HSQC heteronuclear single quantum coherence 
Hz Hertz 
IBX 1-hydroxy-1,2-benziodoxol-3(1H)-one 1-oxide 
IC50 inhibition concentration 50% (conc. at which 50% survive) 
IND indoline derived part of ligand 
IR infra-red spectroscopy 
J 1H-1H coupling constant (in Hz) 
xJPC 13C-31P coupling constant between atoms x bonds apart 
JO Julia olefination 
 xvi 
K Kelvin 
L unspecified ligand, litre 
LDA lithium diisopropylamide 
lit. literature value 
LRMS low resolution mass spectroscopy 
M molar 
m multiplet, medium 
m.p. melting point 
m/z mass to charge ratio 
mCPBA 3-chloroperoxybenzoic acid 
Me methyl 
10-methyl AMPTD (2S,3R,4S,5S,6S,7E,9E,11E)-3-amino-6,10-dimethyl-12-  
 phenyl-2,4,5-trihydroxydodeca-7,9,11-trienoic acid 
MHz megahertz 
min minute(s) 
ml millilitre 
mm millimetre 
mm Hg millimetre of mercury 
mmol millimole 
mol mole 
MOM methoxymethyl 
2-MP 2-methoxypropene 
MPM p-methoxybenzyl 
(R)-MTPA (R)-(+)-α-methoxy-α-(trifluoromethyl)phenylacetic acid 
(S)-MTPA (S)-(-)-α-methoxy-α-(trifluoromethyl)phenylacetic acid 
nm nanometre 
NMR nuclear magnetic resonance 
NOE nuclear Overhauser effect 
NOESY nuclear Overhauser effect spectroscopy 
Nu nucleophile 
PFK perfluorokerosene 
PG generic protecting group 
  xvii  
Ph phenyl 
PHAL phthalazine derived part of ligand 
PMP p-methoxyphenyl 
ppm parts per million 
PPTS pyridinium p-toluenesulfonate 
i-Pr isopropyl 
n-PrOH propanol 
PT 1-phenyl-1H-tetrazol-5-yl 
PTSH 1-phenyl-1H-tetrazole-5-thiol 
q quartet 
quant. quantitative 
quin quintet 
R unspecified alkyl group 
Rf thin layer chromatography retention factor 
RT room temperature 
s singlet, strong 
sat. saturated 
t triplet 
TBDMS tert-butyldimethylsilyl 
TBDPS tert-butyldiphenylsilyl 
TEA triethylamine 
THF tetrahydrofuran 
TLC thin layer chromatography 
TMS tetramethylsilane 
tR HPLC retention time 
Ts p-toluenesulfonyl (tosyl) 
TsOH p-toluenesulfonic acid (tosic acid) 
v/v volume to volume ratio 
w weak 
w/v weight to volume ratio 
WHO World Health Organisation 
wt. weight 
 
